$4.58 Billion is the total value of Rock Springs Capital Management LP's 151 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 30.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGIO | Buy | AGIOS PHARMACEUTICALS INC | $131,352,000 | +20.1% | 2,543,600 | +0.8% | 2.87% | +23.6% |
| HUM | Buy | HUMANA INC | $126,194,000 | +7.9% | 301,000 | +5.6% | 2.75% | +11.1% |
| ZLAB | Buy | ZAI LAB LTDadr | $124,557,000 | +7.7% | 933,500 | +9.2% | 2.72% | +10.8% |
| FPRX | Buy | FIVE PRIME THERAPEUTICS INC | $100,233,000 | +716.6% | 2,660,822 | +268.7% | 2.19% | +741.2% |
| IMCR | New | IMMUNOCORE HLDGS PLCads | $97,583,000 | – | 2,292,285 | +100.0% | 2.13% | – |
| PODD | Buy | INSULET CORP | $96,801,000 | +19.1% | 371,000 | +16.7% | 2.11% | +22.5% |
| ALGN | Buy | ALIGN TECHNOLOGY INC | $96,122,000 | +10.0% | 177,500 | +8.6% | 2.10% | +13.2% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $89,944,000 | +419.5% | 3,569,192 | +33.4% | 1.96% | +434.6% |
| IDXX | Buy | IDEXX LABS INC | $88,076,000 | +41.0% | 180,000 | +44.0% | 1.92% | +45.0% |
| NVTA | Buy | INVITAE CORP | $84,596,000 | +9.2% | 2,213,977 | +19.5% | 1.85% | +12.4% |
| ARGX | Buy | ARGENX SEsponsored adr | $82,617,000 | -2.3% | 300,000 | +4.3% | 1.80% | +0.5% |
| EXAS | Buy | EXACT SCIENCES CORP | $75,115,000 | +16.9% | 570,000 | +17.5% | 1.64% | +20.3% |
| NVRO | Buy | NEVRO CORP | $67,658,000 | -1.0% | 485,000 | +22.8% | 1.48% | +1.8% |
| BOLT | New | BOLT BIOTHERAPEUTICS INC | $51,315,000 | – | 1,559,248 | +100.0% | 1.12% | – |
| MRSN | Buy | MERSANA THERAPEUTICS INC | $44,902,000 | -18.2% | 2,775,127 | +34.5% | 0.98% | -15.8% |
| CGEM | New | CULLINAN ONCOLOGY INC | $44,833,000 | – | 1,075,912 | +100.0% | 0.98% | – |
| KRTX | Buy | KARUNA THERAPEUTICS INC | $44,336,000 | +78.9% | 368,764 | +51.2% | 0.97% | +84.2% |
| CVET | Buy | COVETRUS INC | $41,958,000 | +13.6% | 1,400,000 | +8.9% | 0.92% | +16.9% |
| TVTX | Buy | TRAVERE THERAPEUTICS INC | $36,845,000 | +32.4% | 1,475,564 | +44.5% | 0.80% | +36.3% |
| ARDX | Buy | ARDELYX INC | $34,269,000 | +2.9% | 5,176,561 | +0.6% | 0.75% | +5.9% |
| AZN | New | ASTRAZENECA PLCsponsored adr | $32,318,000 | – | 650,000 | +100.0% | 0.70% | – |
| BIIB | Buy | BIOGEN INC | $31,752,000 | +29.7% | 113,500 | +13.5% | 0.69% | +33.5% |
| MDGL | Buy | MADRIGAL PHARMACEUTICALS INC | $30,237,000 | +5.9% | 258,500 | +0.7% | 0.66% | +9.1% |
| MIRM | Buy | MIRUM PHARMACEUTICALS INC | $29,785,000 | +14.0% | 1,502,800 | +0.4% | 0.65% | +17.3% |
| EVH | New | EVOLENT HEALTH INCcl a | $29,189,000 | – | 1,445,000 | +100.0% | 0.64% | – |
| PRTA | Buy | PROTHENA CORP PLC | $29,061,000 | +112.0% | 1,156,900 | +1.4% | 0.63% | +117.9% |
| ACCD | Buy | ACCOLADE INC | $28,356,000 | +30.4% | 625,000 | +25.0% | 0.62% | +34.3% |
| LUNG | Buy | PULMONX CORP | $27,101,000 | -21.5% | 592,500 | +18.5% | 0.59% | -19.3% |
| ADPT | Buy | ADAPTIVE BIOTECHNOLOGIES COR | $26,169,000 | -30.3% | 650,000 | +2.4% | 0.57% | -28.3% |
| PPD | Buy | PPD INC | $25,542,000 | +42.2% | 675,000 | +28.6% | 0.56% | +46.2% |
| EPZM | Buy | EPIZYME INC | $24,414,000 | -12.0% | 2,802,954 | +9.8% | 0.53% | -9.4% |
| XENT | Buy | INTERSECT ENT INC | $22,555,000 | +40.7% | 1,080,200 | +54.3% | 0.49% | +44.7% |
| ABCM | Buy | ABCAM PLCads | $20,551,000 | +3.1% | 1,069,236 | +15.6% | 0.45% | +5.9% |
| KURA | Buy | KURA ONCOLOGY INC | $20,073,000 | +21.0% | 710,035 | +39.7% | 0.44% | +24.4% |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $17,884,000 | -18.5% | 403,070 | +0.7% | 0.39% | -16.3% |
| SRRA | Buy | SIERRA ONCOLOGY INC | $17,529,000 | +92.7% | 1,017,358 | +79.3% | 0.38% | +97.9% |
| GMDA | Buy | GAMIDA CELL LTD | $16,991,000 | -3.3% | 2,100,300 | +0.3% | 0.37% | -0.5% |
| PRLD | Buy | PRELUDE THERAPEUTICS INC | $16,387,000 | -36.4% | 378,195 | +4.9% | 0.36% | -34.6% |
| DVAX | Buy | DYNAVAX TECHNOLOGIES CORP | $16,303,000 | +122.1% | 1,658,520 | +0.6% | 0.36% | +128.2% |
| MREO | New | MEREO BIOPHARMA GROUP PLCads | $15,148,000 | – | 4,494,869 | +100.0% | 0.33% | – |
| AKRO | Buy | AKERO THERAPEUTICS INC | $15,119,000 | +13.7% | 521,171 | +1.1% | 0.33% | +17.0% |
| EPIX | New | ESSA PHARMA INC | $14,613,000 | – | 503,035 | +100.0% | 0.32% | – |
| OLK | New | OLINK HLDG ABsponsored ads | $14,400,000 | – | 400,000 | +100.0% | 0.31% | – |
| TBPH | Buy | THERAVANCE BIOPHARMA INC | $13,932,000 | +15.6% | 682,600 | +0.6% | 0.30% | +18.8% |
| CERE | Buy | CEREVEL THERAPEUTICS HLDNG I | $13,800,000 | -16.7% | 1,005,100 | +0.6% | 0.30% | -14.2% |
| APLT | Buy | APPLIED THERAPEUTICS INC | $13,160,000 | -6.0% | 701,680 | +10.4% | 0.29% | -3.4% |
| RYTM | Buy | RHYTHM PHARMACEUTICALS INC | $12,747,000 | -12.6% | 599,280 | +22.2% | 0.28% | -10.0% |
| MGNX | Buy | MACROGENICS INC | $12,532,000 | +77.1% | 393,479 | +27.1% | 0.27% | +82.0% |
| INNV | New | INNOVAGE HLDG CORP | $12,250,000 | – | 475,000 | +100.0% | 0.27% | – |
| PRTK | Buy | PARATEK PHARMACEUTICALS INC | $11,894,000 | +13.1% | 1,684,714 | +0.2% | 0.26% | +16.1% |
| ANAB | Buy | ANAPTYSBIO INC | $11,534,000 | +73.4% | 535,232 | +73.0% | 0.25% | +78.7% |
| CNMD | Buy | CONMED CORP | $11,111,000 | +27.2% | 85,085 | +9.1% | 0.24% | +30.8% |
| FGEN | Buy | FIBROGEN INC | $10,853,000 | -5.4% | 312,687 | +1.1% | 0.24% | -2.5% |
| TARA | Buy | PROTARA THERAPEUTICS INC | $10,860,000 | -30.3% | 689,942 | +7.3% | 0.24% | -28.2% |
| TBIO | Buy | TRANSLATE BIO INC | $10,717,000 | -9.6% | 649,900 | +1.0% | 0.23% | -6.8% |
| NGM | Buy | NGM BIOPHARMACEUTICALS INC | $10,605,000 | -2.9% | 364,800 | +1.2% | 0.23% | -0.4% |
| CGEN | Buy | COMPUGEN LTDord | $10,475,000 | -23.7% | 1,219,488 | +7.6% | 0.23% | -21.3% |
| RXDX | New | PROMETHEUS BIOSCIENCES INC | $10,497,000 | – | 574,858 | +100.0% | 0.23% | – |
| KDNY | Buy | CHINOOK THERAPEUTICS INC | $10,459,000 | -1.4% | 673,049 | +0.6% | 0.23% | +1.3% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $10,248,000 | +29.4% | 572,500 | +11.2% | 0.22% | +33.3% |
| KNTE | Buy | KINNATE BIOPHARMA INC | $10,170,000 | -21.3% | 326,386 | +0.5% | 0.22% | -19.0% |
| AUPH | Buy | AURINIA PHARMACEUTICALS INC | $10,149,000 | -5.1% | 781,569 | +1.0% | 0.22% | -2.6% |
| OHPAU | New | ORION ACQUISITION CORPunit 02/19/2026 | $10,000,000 | – | 1,000,000 | +100.0% | 0.22% | – |
| DSGN | New | DESIGN THERAPEUTICS INC | $9,785,000 | – | 327,250 | +100.0% | 0.21% | – |
| NRIX | Buy | NURIX THERAPEUTICS INC | $9,667,000 | +14.3% | 310,950 | +20.9% | 0.21% | +17.9% |
| LEGN | Buy | LEGEND BIOTECH CORPsponsored ads | $9,072,000 | +4.1% | 312,618 | +1.0% | 0.20% | +7.0% |
| BCEL | Buy | ATRECA INC | $6,959,000 | -4.5% | 453,930 | +0.6% | 0.15% | -1.9% |
| CHMA | Buy | CHIASMA INC | $6,806,000 | -26.8% | 2,174,583 | +1.8% | 0.15% | -24.9% |
| Buy | TRILLIUM THERAPEUTICS INC | $6,667,000 | -26.7% | 620,800 | +0.4% | 0.14% | -24.9% | |
| ACRX | Buy | ACELRX PHARMACEUTICALS INC | $6,435,000 | +37.2% | 3,785,457 | +0.1% | 0.14% | +41.4% |
| FATE | New | FATE THERAPEUTICS INC | $5,772,000 | – | 70,000 | +100.0% | 0.13% | – |
| DXCM | New | DEXCOM INC | $5,391,000 | – | 15,000 | +100.0% | 0.12% | – |
| PHAS | Buy | PHASEBIO PHARMACEUTICALS INC | $5,377,000 | +21.8% | 1,553,974 | +18.2% | 0.12% | +24.5% |
| GRTX | Buy | GALERA THERAPEUTICS INC | $5,012,000 | -13.7% | 568,252 | +0.1% | 0.11% | -11.4% |
| NUVB | New | NUVATION BIO INC | $4,202,000 | – | 402,088 | +100.0% | 0.09% | – |
| CNTB | New | CONNECT BIOPHARMA HLDGS LTDads | $2,204,000 | – | 119,114 | +100.0% | 0.05% | – |
| FSII | New | FS DEVELOPMENT CORP II | $2,085,000 | – | 209,332 | +100.0% | 0.04% | – |
| NUVBWS | New | NUVATION BIO INC*w exp 07/07/202 | $358,000 | – | 134,028 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.